trial

The Impact of Caffeine on Cognition in Schizophrenia

NCTId NCT02832401
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 24 (actual)
Sponsored by Nova Scotia Health Authority
Primary completion 2018-08-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2016-09-02
Primary completion
2018-08-02
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Caffeine

Sponsors

Nova Scotia Health AuthorityLead Sponsor
Dalhousie UniversityCollaborator
Mount Saint Vincent UniversityCollaborator

Investigators

1
Derek Fisher, Ph.D.Principal Investigator

Sites

1 total
Halifax, Canada

Facts & assertions

4 sourced
Enrollment
24
Phase
NA
Primary Completion Date
2018-08-02
Status
COMPLETED
relationships
The graph out of here
drug
Caffeine
drug
lead_sponsor
Nova Scotia Health Authority
company
collaborator
Dalhousie University
company
Mount Saint Vincent University
company
indication
Schizophrenia
indication
Schizophrenia
indication
Caffeine
indication
investigator
Derek Fisher, Ph.D.
person